[1] |
中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组.中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2010[J].中华神经科杂志,2010,43(2):154. |
[2] |
KERNAN WN,OVBIAGELE B,BLACK HR,et al.Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2014,45(7):2160. |
[3] |
ERIKSSON P.Creative cost-effectiveness analysis of CAPRIE data dust in our eyes[J].Am J Med,2005,118:199. |
[4] |
HO PM,MADDOX TM,WANG L,et al.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J].JAMA,2009,301:937. |
[5] |
SOFI F,MARCUCCI R,GORI AM,et al.Clopidogrel non-responsiveness and risk of cardiovascular morbidity.An updated meta-analysis[J].Thromb Haemost,2010,103:841. |
[6] |
NGUYEN TA,DIODAT JQ,PHARAND C.Resistance to clopidogrel:a review of the evidence[J].J Am Coll Cardiol,2005,45:1157. |
[7] |
SCOTT SA,SANGKUHL K,GARDNER EE,et al.Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19(CYP2C19) genotype and clopidogrel therapy[J].Clin Pharmacol Ther,2011,90(2):328. |
[8] |
KAZUI M,NISHIYA Y,ISHIZUKA T,et al.Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J].Drug Metab Dispos,2009,38(1):92. |
[9] |
MEGA JL,CLOSE SL,WIVIOTT SD,et al.CytochromeP-450 polymorphisms and response to clopidogrel[J].Curr Atheroscler Rep,2009,360(3):2250. |
[10] |
MAN M,FARMEN M,DUMAUAL C,et al.Genetic variation in metabolizing enzyme and transporter genes:comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans[J].J Clin Pharmacol,2010,50(8):929. |
[11] |
MORAIS SM,WILKINSON GR,BLAISDELL J,et al.The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans[J].J Biol Chem,1994,269(22):15419. |
[12] |
MEGA JL,CLOSE SL,WIVIOTT SD,et al.Cytochrome p-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(4):3542. |
[13] |
MEGA JL,CLOSE SL,WIVIOTT SD,et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial:a pharmacogenetic analysis[J].Lancet,2010,376(9749):1312. |
[14] |
COLLET JP,HULOT JS,PENA A,et al.Cytochrome P4502C19 polymorphism in young patients treated with clopidogrel after myocardial infarction:a cohort study[J].Lancet,2009,373(9660):309. |
[15] |
SHULDINER AR,O'CONNELL JR,BLIDEN KP,et al.Association of cytochrome P4502C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA,2009,302(8):849. |